VentureBeat

Uber, an also-ran social network turned microblog platform, closes down — Investors included Universal Music Group and Sterling Stamos Co-Investors fund. The company claimed that it closed down due to economic issues, as you can read on its site. More on PaidContent.

Mobile payment company Transaction Wireless raises $2.25 million — Funding comes from Mission Ventures and Okapi Ventures.

House debates about how its members can use web video, devolves into childish squabbling — The Senate has already avoided such squabbling and worked out its own rules.

Avigo Capital Partners is raising a $300 million fund — The New Delhi, India-based private equity fund plans to close this third fund by the end of the year.

Teen virtual world Habbo may be making up to $38 million in revenue a year? — Jeremy Liew looks at various rumors about how much the company could be making.

Yahoo president Sue Decker defends “Yahoogle” deal — More on All Things D.

Immunotherapeutics company Macrogenics raises $25 million — Investors include Nextech Ventures, Arcus Ventures, Innovis Investments and Eli Lilly and Company.

Half a million sign up for EA’s Warhammer Online — This comes a week after launch.

Santa Monica, Calif.-based Agensys, a biotech focused on new cancer drugs, raised $41 million in a fourth funding round. Duquesne Capital Management and JAFCO led the round, joined by Innovis Investments, Nextech Venture, Bear Stearns Health Innoventures, Alta Partners, HBM BioVentures, Lombard Odier Darier Hentsch & Cie, H&Q Life Sciences Investments, and Orbimed Associates.

Agensys develops monoclonal antibodies designed to target surface proteins or other molecules that specifically identify tumor cells. Its first drug candidate, AGS-PSCA, targets a protein known as prostate stem-cell antigen, which the company claims is found in a majority of patients with prostate, pancreatic and bladder cancer. In conjunction with Merck, Agensys launched an early stage phase I trial of AGS-PSCA in 2005 that apparently demonstrated the drug’s safety, although the company hasn’t had much to say about the drug since.

In January, the company also struck an agreement with Seattle Genetics to co-develop “antibody-drug conjugates,” which combine a toxic chemotherapy drug with an antibody designed to help it hone in on a targeted tumor.

Agensys was founded in 1997 as UroGenesys, but updated its name in 2001. It had previously raised $62.1 million in three rounds.

San Diego’s TargeGen, a biotechnology targeting disease treatments related to abnormal blood-vessel growth, raised $40 million in a fourth funding round. New investors included Innovis Investments, VantagePoint Venture Partners and CTI Life Sciences Fund, joined by existing investors Forward Ventures, Enterprise Partners, Chicago Growth Partners.

TargeGen’s potential disease targets range from eye diseases such as age-related macular degeneration (AMD) to cancer to heart disease. Its leading drug candidate, TG100801, completed an early-stage phase I trial in AMD-related vision loss in February, but said only that the drug appeared safe and “well tolerated.”